Stay updated with breaking news from Barry Greene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAMBRIDGE - Sage Therapeutics, Inc. announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor in people with...
CAMBRIDGE, Mass. -March 26, 2024 -- Sage Therapeutics, Inc. today announced that Steve Paul, M.D. will retire from the Company's Board of Directors at the end of his current term. Dr. Paul...
Despite missing out on an FDA approval for major depressive disorder, Zurzuvae appears to be a strong asset for Sage Therapeutics, with high growth potential in 2024.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Call Transcript February 14, 2024 Sage Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. Welcome to SAGE Therapeutics’ Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator […]
Highlights Key Pipeline Progress and Commercial Launch of ZURZUVAE